Immunomodulatory effects of erythromycin and its derivatives on human T-lymphocyte in vitro

Immunopharmacology and Immunotoxicology

Volumn 29, Issue 3-4, 2007, Pages 587-596

  Wu, Lan ^a   Zhang, Weige ^b   Tian, Liang ^b   Bao, Kai ^b   Li, Pengfei ^a   Lin, Jie ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Erythromycin Derivative; Immunomodulatory Effect; Jurkat T Cells; Nuclear Factor Kappa B

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ERYTHROMYCIN; ERYTHROMYCIN 1; ERYTHROMYCIN 2; ERYTHROMYCIN DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROLIDE; MESSENGER RNA; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; LEUKEMIA CELL LINE; LYMPHOCYTE PROLIFERATION; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; WESTERN BLOTTING;

ANTI-BACTERIAL AGENTS; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; ERYTHROMYCIN; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC FACTORS; IN SITU NICK-END LABELING; JURKAT CELLS; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STIMULATION, CHEMICAL; T-LYMPHOCYTES; TETRAZOLIUM SALTS; THIAZOLES;

EID: 37149011743     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970701692841     Document Type: Article

References (20)

1. Henninger, T.C. Recent progress in the field of macrolide antibiotics. Expert. Opin. Ther. Pat. 2003, 13 (6), 787-805.
2. Sakito, O.; Kadota, J.; Kohno, S.; Abe, K.; Shirai, R.; Hara, K. Interleukin-1 beta, tumor necrosis factor-alpha, and interleukin-8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996, 63 (1), 42-48.
3. Koyama, H.; Geddes, D.M. Erythromycin and diffuse panbronchiolitis. Thorax 1997, 52(10), 915-918.
4. Culic, O.; Erakovic, V.; Pamam, M.J. Anti-inflammatory effects of macrolide antibiotics. Eur. J. Pharmacol. 2001, 429(1-3), 209-229.
5. Takizawa, H.; Desaki, M.; Ohtoshi, T.; Kawasaki, S.; Kohyama, T.; Sato, M.; Tanaka, M.; Kasama, T.; Kobayashi, K.; Nakajima, J.; Ito, K. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am. J. Resp. Crit. Care. Med. 1997, 156 (1), 266-271.
6. Khair, O.A.; Devalia, J.L.; Abdelaziz, M.M.; Sapsford, R.J.; Davies, R.J. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur. Respir. J. 1995, 8(9), 1451-1457.
7. Takizawa, H.; Desaki, M.; Ohtoshi, T.; Kikutani, T.; Okazaki, H.; Sato, M.; Akiyama, N.; Shoji, S.; Hiramatsu, K.; Ito, K. Erythromycin suppresses interleukin-6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action. Biochem. Biophys. Res. Commun. 1995, 210(3), 781-786.
8. Mercurio, T.; Mereu, A.; Morazzoni, G.; Meriggi, E.; Napoletano, M.; Pellacini, F. New erythromycin derivatives as potent anti-inflammatory agents. Drug Future 2004, 29(Suppl. A), 387.
9. Stenmark, H.G.; Brazzale, A.; Ma, Z. Biomimetic synthesis of macrolide/ketolide metabolites through a selective N-demethylation reaction. J. Org. Chem. 2000, 65 (12), 3875-3876.
10. Kibwage, I.O.; Busson, R.; Janssen, G.; Hoogmartens, J.; Vanderhaeghe, H. Translactonization in erythromycins. J. Org. Chem. 1987, 52 (19), 990-996.
11. Hong, S.Y.; Yoon, W.H.; Park, J.H.; Kang, S.G.; Ahn, J.H.; Lee, T.H. Involvement of two NF-kappa B binding elements in tumor necrosis factor alpha-, CD40-, and Epstein-Barr virus latent membrane protein 1-mediated induction of the cellular inhibitor of apoptosis protein 2 gene. J. Biol. Chem. 2000, 275 (24), 18022-18028.
12. Thompson, C.B. Apoptosis in the pathogenesis and treatment of disease. Science 1995, 267 (5203), 1456-1462.
13. Parnham, M.J.; Culić, O.; Eraković, V.; Munić, V.; Popović-Grle, S.; Barisić, K.; Bosnar, M.; Brajsa, K.; Cepelak, I.; Cuzić, S.; Glojnarić, I.; Manojlović, Z.; Novak-Mircetić, R.; Oresković, K.; Pavicid-Beljak, V.; Radosević, S.; Sucić, M. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur. J. Pharmacol. 2005, 517 (1-2), 132-143.
14. Hodge, S.; Hodge, G.; Brozyna, S.; Jersmann, H.; Holmes, M.; Reynolds, P.N. Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur. Respir. J. 2006, 28 (3), 486-495.
15. Ichiyama, T.; Nishikawa, M.; Yoshitomi, T.; Hasegawa, S.; Matsubara, T.; Hayashi, T.; Furukawa, S. Clarithromycin inhibits NF-κB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob. Agents Chemother. 2001, 45 (1), 44-47.
16. Sugiyama, K.; Shirai, R.; Mukae, H.; Ishimoto, H.; Nagata, T.; Sakamoto, N.; Ishii, H.; Nakayama, S.; Yanagihara, K.; Mizuta, Y.; Kohno, S. Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells. Clin. Exp. Immunol. 2007, 147 (3), 540-546.
17. Aoshiba, K.; Nagai, A.; Konno, K. Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob. Agents Chemother. 1995, 39 (4), 872-877.
18. Aoki, Y.; Kao, P.N. Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. Antimicrob. Agents Chemother. 1999, 43 (11), 2678-2684.
19. Desaki, M.; Takizawa, H.; Ohtoshi, T.; Kasama, T.; Kobayashi, K.; Sunazuka, T.; Omura, S.; Yamamoto, K.; Ito, K. Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem. Biophys. Res. Commun. 2000, 267 (1), 124-128.
20. Takahashi, H.; Hashimoto, Y.; Ishida-Yamamoto, A.; Iizuka, H. Roxithromycin suppresses involucrin expression by modulation of activator protein-1 and nuclear factor-kappaB activities of keratinocytes. J. Dermatol. Sci. 2005, 39 (3), 175-182.